surmount-1 tirzepatide non-diabetic weight loss Gastrointestinal tolerability and reduction associated with in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT‐1 to ‐4 trials - Rubino - 2025 SURMOUNT-1: Tirzepatide Drastically Reduces Weight
Description
Early fullness, reduced cravings, and smaller portion tolerance often increase as the dose is gradually adjusted
was on advisory boards for Adocia, Novo Nordisk, and Zealand
Raufman, J
Six studies assessed all three eligible tirzepatide maintenance doses (5, 10 and 15 mg once-weekly), while one study included two arms with a maintenance dose of 15 mg but with two different dose-escalation regimens [18]
